MYERS KENNY
Known title: DirectorCIK: 0001905102
Associated companies
Transaction History
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 9/9/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 25,000 | $0 | 4/10/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 6/3/2024 | View on chart |
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 9/9/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 25,000 | $0 | 4/10/2025 | View on chart |
| MGRX | ▲ Buy | Grant | 100,000 | $0 | 6/3/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement
Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.
MGRX Shares Drop 12% After Hours Amid $2.5M Investment Announcement. Mangoceuticals shares fell 12% in after‑hours trading after the company announced a $2.5 million investment in its MangoRx IP. The deal provides an initial $1.75 million tranche and additional funding from strategic investors. Despite the funding, the market reacted negatively, pulling the stock lower. The move highlights the volatility around the company’s valuation.